GC Biopharma Corp. · KRX:006280

GC Biopharma Corp. financial statements

GC Biopharma Corp.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.99T1.68T1.63T1.71T1.54T1.50T1.37T1.33T1.29T1.20T
Cost of revenue1.44T1.20T1.14T1.13T1.02T1.06T997.4B989.0B921.1B845.8B
Gross profit554.1B481.9B484.6B581.8B520.6B440.6B372.3B345.9B366.8B352.1B
Research and development152.9B166.2B173.5B191.3B146.0B138.0B126.7B122.0B108.6B112.3B
Selling, general and administrative166.3B130.1B134.4B165.1B169.1B145.2B112.3B92.2B84.4B82.3B
Operating income69.1B32.1B34.4B81.3B73.7B50.3B40.3B50.2B90.3B78.5B
Depreciation and amortization87.7B81.0B75.9B65.1B55.9B48.8B46.7B40.1B36.7B31.1B
EBITDA156.8B113.1B110.3B146.4B129.6B99.1B87.0B90.4B127.0B109.5B
Interest expense50.3B40.4B28.5B18.4B12.5B10.4B9.61B7.61B00
Income before tax-35.3B-41.1B-27.1B85.7B172.6B104.5B-6.14B50.2B72.2B79.5B
Income tax35.6B15.4B5.15B15.9B15.4B14.4B
Net income-4.67B-26.3B-26.6B65.5B123.2B81.0B-3.64B34.4B53.2B63.0B
Earnings per share, basic-409.51-2,302.62-2,333.425,734.8710,795.577,101.34-318.723,016.644,665.36

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents49.4B22.6B49.7B105.4B186.1B232.3B98.5B96.6B171.0B56.9B
Short-term investments1.43B1.43B5.80B6.94B16.9B23.2B43.1B10.1B268.0M60.3B
Receivables402.7B386.5B437.0B394.2B413.8B402.1B405.2B391.2B368.2B345.0B
Inventory891.6B746.6B516.2B442.4B455.0B437.1B406.6B386.9B381.3B320.8B
Current assets1.37T1.20T1.04T980.4B1.09T1.13T961.8B893.4B926.5B801.4B
Property, plant and equipment899.8B751.1B718.7B559.7B552.0B554.0B
Goodwill118.1B125.6B142.5B142.5B142.5B10.1B10.1B10.2B15.1B17.8B
Total assets2.97T2.74T2.64T2.53T2.46T2.15T1.96T1.72T1.70T1.55T
Accounts payable177.3B156.8B143.8B121.3B119.5B134.8B139.3B144.9B158.8B118.3B
Current liabilities1.15T769.5B868.9B540.7B552.9B589.4B401.4B303.5B260.1B303.3B
Long-term debt253.5B339.5B84.9B278.8B280.3B194.2B272.1B263.3B307.0B149.5B
Total liabilities1.58T1.26T1.10T958.9B962.4B882.1B775.2B597.2B594.9B491.6B
Shareholders' equity1.22T1.25T1.30T1.33T1.27T1.12T1.05T1.06T1.04T993.1B
Shares outstanding11.4M11.4M11.4M11.4M11.4M11.4M11.4M11.4M11.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations99.5B-53.5B-5.47B119.2B126.0B36.0B40.3B14.4B57.9B-1.74B
Capital spending-105.3B-42.4B-126.0B-94.7B-102.3B-82.9B-127.5B-41.4B-29.5B-98.7B
Free cash flow-5.82B-95.9B-131.5B24.5B2.44B-65.4B-107.3B-50.6B2.31B-100.4B
Cash from investing-132.1B29.7B-177.9B-86.1B14.8B-111.1B
Cash from financing-41.3B81.0B140.8B-4.51B48.2B110.6B
Dividends paid-18.8B-19.5B-24.8B-24.0B-18.5B-12.7B-12.4B-15.3B-15.3B-20.5B
Share buybacks-21.8B
Change in cash26.8B-27.1B-55.7B-80.7B-46.2B133.8B1.83B-74.3B114.1B-816.1M